Pharmaceutical giants continue to reconsider investments in the UK amid evolving market conditions. AstraZeneca paused a $271 million expansion at its Cambridge research site, following similar retrenchments by Merck and Eli Lilly. Lilly is also reportedly reconsidering its UK Gateway Labs biotech incubator plans due to concerns over industry outlook and government funding. These development signals a notable recalibration of biopharma operations and investments in the UK market.